Non-alcoholic fatty liver disease (NAFLD) and the quest for effective treatments

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide, affecting 24% of the population, and is impacting on global public health care with a considerable financial burden (1). NAFLD encompasses a wide disease spectrum ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis.